Trial Profile
Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Oxaliplatin
- Indications Gastric cancer; Liver metastases
- Focus Biomarker; Therapeutic Use
- 15 Jan 2018 Status changed from recruiting to completed.
- 06 Jun 2017 Results of a biomarker analysis presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 16 Feb 2017 Status changed from active, no longer recruiting to recruiting.